Sigma Planning Corp Invests $236,000 in Ascendis Pharma A/S (NASDAQ:ASND)

Sigma Planning Corp purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,515 shares of the biotechnology company's stock, valued at approximately $236,000.

A number of other large investors have also recently bought and sold shares of ASND. Virtus ETF Advisers LLC boosted its holdings in shares of Ascendis Pharma A/S by 3.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company's stock valued at $368,000 after buying an additional 100 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $28,000. GF Fund Management CO. LTD. boosted its holdings in shares of Ascendis Pharma A/S by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,544 shares of the biotechnology company's stock valued at $241,000 after buying an additional 278 shares during the last quarter. Mariner LLC raised its stake in Ascendis Pharma A/S by 31.0% in the 4th quarter. Mariner LLC now owns 2,160 shares of the biotechnology company's stock valued at $297,000 after acquiring an additional 511 shares during the period. Finally, Geode Capital Management LLC raised its stake in Ascendis Pharma A/S by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 57,077 shares of the biotechnology company's stock valued at $7,858,000 after acquiring an additional 629 shares during the period.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock traded down $0.84 during trading hours on Friday, hitting $167.47. The company's stock had a trading volume of 421,932 shares, compared to its average volume of 412,063. The business has a 50 day moving average price of $170.63 and a two-hundred day moving average price of $155.66. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $183.00. The company has a market cap of $10.24 billion, a PE ratio of -26.67 and a beta of 0.38.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to analysts' expectations of $98.56 million. As a group, research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ASND shares. Citigroup increased their price target on Ascendis Pharma A/S from $213.00 to $243.00 and gave the company a "buy" rating in a research note on Friday, July 11th. Bank of America increased their price objective on Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research report on Monday, June 9th. Oppenheimer reiterated an "outperform" rating and set a $224.00 price objective (up previously from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Royal Bank Of Canada increased their price objective on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Finally, JPMorgan Chase & Co. increased their price objective on Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research report on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S has an average rating of "Moderate Buy" and a consensus price target of $223.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.